Results 1 to 10 of about 98,296 (378)
Bisphosphonates for osteoporosis [PDF]
New England Journal of Medicine, 2001 Bisphosphonates are compounds characterized by a P-C-P structure. They act essentially on bone, inhibiting bone resorption. Through this mechanism they decrease bone loss, increase bone mineral density, and decrease bone turnover. They are therefore administered in diseases with elevated bone destruction, such as Paget's disease, metastatic bone ...
Kenichiro Narusawa, Toshitaka Nakamura
+12 more sources
Preventing bone loss after renal transplantation with bisphosphonates: We can… but should we? [PDF]
Kidney International, 2000 Bisphosphonates are valuable agents for the treatment of post-menopausal osteoporosis (PMO), hypercalcemia of malignancy, and osteolytic bone metastases. Oral bisphosphonates are used mainly to treat PMO and are not associated with significant nephrotoxicity.
Thomas J. Weber, L. Darryl Quarles
openalex +3 more sources
Endocrinology and Metabolism Clinics of North America, 2003 Osteoporosis is the result of bone loss due to an imbalance in bone turnover such that bone resorption exceeds bone formation. Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. In clinical studies, several bisphosphonates prevent bone loss, preserve
Julie T, Lin, Joseph M, Lane
openaire +7 more sources
Frontiers in Medicine, 2021 Bisphosphonate has great potential in KOA therapy, but whether the anti-resorption mechanism of bisphosphonate aggravates sclerosis of subchondral bone remains unclear.
Mingyang Li +7 more
doaj +1 more source
Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients
Brazilian Journal of Otorhinolaryngology, 2022 Introduction: Medication-related osteonecrosis of the jaws is a severe complication of the use of antiresorptive and antiangiogenic therapy, with limited treatment options and great impact on patient’s quality pf life.
Aristilia Pricila Tahara Kemp +7 more
doaj +1 more source
How much we know about bisphosphonate lesions [PDF]
Acta Stomatologica Naissi, 2016 Introduction: Bisphosphonate drugs are used in the treatment of the osteoporosis and malignant processes in the bone tissue. As a result of this use bisphosphonate lesions are formed in bone tissue and oral mucosis, which representing a remarkable ...
Pešić Zoran +2 more
doaj +1 more source
Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. [PDF]
, 2013 Osteoarthritis (OA) is the most common form of arthritis worldwide. Pain and reduced function are the main symptoms in this prevalent disease. There are currently no treatments for OA that modify disease progression; therefore analgesic drugs and joint ...
AD Beswick +37 more
core +12 more sources
Medical and Health Science Journal, 2020 INTRODUCTION Osteogenesis imperfecta (OI) or brittle bone disease is a connective tissue formation disorder that is generally characterized by bone fragility, osteopenia, blue sclera, dentinogenesis imperfecta (DI), and hearing loss.
Baskoro Kusumo Riswanto +1 more
doaj +1 more source
Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]
, 2011 The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong +7 more
core +4 more sources
Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14 Years
JBMR Plus, 2021 Oral bisphosphonates are the primary medication for osteoporosis, but concerns exist regarding potential bone‐quality changes or low‐energy fractures.
Hartmut H Malluche +5 more
doaj +1 more source